Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP.
about
Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximabMHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancersThe copper chelator ATN-224 induces caspase-independent cell death in diffuse large B cell lymphomaDNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma.Switching to BCL-6 Negativity in Relapsed Diffuse Large B Cell Lymphoma Correlated with More Aggressive Disease Course.Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.Genetic lesions in diffuse large B-cell lymphomasPrognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.Cutaneous presentation of Double Hit Lymphoma: A Case Report With Review of the Literature.Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.Prognostication of diffuse large B-cell lymphoma in the rituximab era.Molecular genetic characterization of lymphoma: application to cytology diagnosis.Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.Genetic and molecular targets in lymphoma: implications for prognosis and treatment.A Novel Non-Immunoglobulin (non-Ig)/BCL6 Translocation in Diffuse Large B-Cell Lymphoma Involving Chromosome 10q11.21 Loci and Review on Clinical Consequences of BCL6 Rearrangements.Expression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).BCL2 mutations in diffuse large B-cell lymphoma.Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma.Double-Hit Large B Cell Lymphoma.Long noncoding RNA identification in lymphoma.A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients.Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.An intravascular large B-cell lymphoma with a t(3;14)(q27;q32) translocationAge-Related Chromosomal Aberrations in Patients with Diffuse Large B-Cell Lymphoma: An Approach
P2860
Q28256567-0F7B20EC-1BDA-4708-8589-D061D5BEAAEBQ28306431-A8EBE9A8-D148-429A-B63A-9AF6230D8A6CQ28389285-523D9264-DFA0-422C-BBF2-65B78840D5ECQ34360406-566A3B21-116F-406A-BEC8-A9EE82A2AF2AQ34569062-304A87E3-366A-43BD-B8CB-94CE6CC7007CQ35755485-72F3F711-6A5D-4EF4-8D42-78F40A8F182CQ35974341-F796A8D5-1C15-401A-8777-01021679D704Q36771814-8B494193-68FB-4E03-B380-94A1BA09ACC6Q36799405-F75246E8-EFE9-4057-A22F-9443391E0EC7Q37109671-C9F41CD1-1DC9-45CA-9293-BC598591F32BQ37833087-F45AB801-49D9-4A70-9496-469CC357FE45Q38012420-DC2C7F86-C80A-4025-ADD8-2F512124EC3DQ38138170-B62DD6E8-5ADD-4704-ABCA-197A5CFF1E69Q38294626-585AF933-8FEE-4610-81E5-A5F3B3E7036CQ38576194-6BD7FEB5-9594-4C93-9FB4-F07DE617F04CQ41788230-78266840-1826-4C4F-9EC2-7A52519BDEB6Q42772985-CE9AA89F-D706-4D03-AB95-0CA13E1BD42DQ43764468-CC654668-7A19-49D9-8A60-22A1E0681688Q45304558-B258CCAE-68D6-4546-B37B-B8EAE317B535Q47848636-71FF970C-5891-4D82-BDE0-7D5A95B3C0ABQ48018366-8DCB1BA3-E024-48D3-B23F-85232A5604AEQ53079458-9A51CD57-5693-4E50-B6D9-B9A255AA729CQ57642906-57AACA44-53F9-479F-948D-81C879094C4DQ58761499-7AF69594-F04F-475F-B044-46441961662A
P2860
Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Correlations between BCL6 rear ...... a treated with CHOP or R-CHOP.
@ast
Correlations between BCL6 rear ...... a treated with CHOP or R-CHOP.
@en
Correlations between BCL6 rear ...... a treated with CHOP or R-CHOP.
@nl
type
label
Correlations between BCL6 rear ...... a treated with CHOP or R-CHOP.
@ast
Correlations between BCL6 rear ...... a treated with CHOP or R-CHOP.
@en
Correlations between BCL6 rear ...... a treated with CHOP or R-CHOP.
@nl
prefLabel
Correlations between BCL6 rear ...... a treated with CHOP or R-CHOP.
@ast
Correlations between BCL6 rear ...... a treated with CHOP or R-CHOP.
@en
Correlations between BCL6 rear ...... a treated with CHOP or R-CHOP.
@nl
P2093
P2860
P50
P1433
P1476
Correlations between BCL6 rear ...... a treated with CHOP or R-CHOP.
@en
P2093
Christian Steidl
Douglas E Horsman
Guangming Han
Jesse Shustik
Laurie H Sehn
Nathalie A Johnson
Susana Ben Neriah
P2860
P304
P356
10.3324/HAEMATOL.2009.007203
P577
2009-10-01T00:00:00Z